SCHEMBL7942332

SCHEMBL7942332

CCNC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
BLM P54132 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 2/20 0.34
ACHE P22303 3/20 0.33
BCHE P06276 3/20 0.33
HTT P42858 2/20 0.32
HPGD P15428 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23221249 0.88 EPHX1 (0.33) EPHX1KMT2AMEN1KDM4EPOLB
SCHEMBL14848322 0.85 BCHE (0.42) EPHX1KMT2AMEN1MAPTL3MBTL1
SCHEMBL9002830 0.82 ACHE (0.49) EPHX1ALDH1A1ACHEBCHE
SCHEMBL17739994 0.81 EPHX1 (0.51) EPHX1ACHE
SCHEMBL15490380 0.80 KMT2A (0.33) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL16470438 0.80 KDM4E (0.41) EPHX1KMT2AMEN1KDM4EPOLB
SCHEMBL7939869 0.80 EPHX1 (0.54) EPHX1ACHE
SCHEMBL27035916 0.80 EPHX1 (0.54) EPHX1ACHE
SCHEMBL11709959 0.80 EPHX1 (0.54) EPHX1ACHE
SCHEMBL11752934 0.79 MEN1 (0.47) EPHX1KMT2AMEN1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6245478-B1 Resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-06-12 US claimed
EP-3797797-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST Novartis AG (CH) 2021-03-31 EP disclosed
EP-3753578-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF Novartis AG (CH) 2020-12-23 EP disclosed
EP-3368092-B9 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST NOVARTIS AG (CH) 2020-07-29 EP disclosed
EP-3154997-B1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2020-02-19 EP disclosed
EP-3082877-B1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2019-08-28 EP disclosed
WO-2018116178-A1 ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2018-06-28 WO disclosed
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-12-14 US disclosed
WO-2017191579-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS AG (CH) 2017-11-09 WO disclosed
WO-2017072662-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST NOVARTIS AG (CH) 2017-05-04 WO disclosed
US-20160311853-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160139136-A1 RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS WATERS TECHNOLOGIES CORPORATION (US) 2016-05-19 US disclosed
US-20160139136-A1 RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS WATERS TECHNOLOGIES CORPORATION (US) 2016-05-19 US disclosed
WO-2015189791-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2015-12-17 WO disclosed
US-6245478-B1 Resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE RNGTT, RNASE1, RNMT EPHX1 4394/4885KMT2A 2505/4885MEN1 1913/4885
US-20160311853-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF CD47, NGLY1, VIP EPHX1 3068/4885KMT2A 4528/4885MEN1 1012/4885
US-20160139136-A1 RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS FUT5, FUT6, CSGALNACT1 EPHX1 3753/4885KMT2A 3081/4885MEN1 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.